Case Report: Treatment of Alectinib in NSCLC With Brain Metastasis Patient Refractory to Radiotherapy After Resistance to Crizotinib

BackgroundBrain metastasis is the most common form of tumor recurrence after resistance to crizotinib in patients with anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC).The treatment of brain metastasis in patients with ALK-positive NSCLC requires a multidisciplinary approach, including AEG IKE64450FB Electric Induction H

read more